The microbiome, the vast, tangled ecosystem of bacteria, fungi and other microbes that live in and on us, is increasingly recognised as a major factor in health, nutrition and drug response. A new startup called Outpost Bio is trying to make that complexity easier to work with, and investors have just put money behind the idea.

Outpost Bio announced a $3.5 million pre-seed funding round co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined and several strategic family offices and angel investors. The capital will support development of its experimental and modelling platforms, which are designed to combine automated lab work with machine intelligence in a tight feedback loop.

Traditional biology research often separates data collection from analysis: scientists run experiments, then hand results to statisticians or AI models after the fact. Outpost Bio’s approach attempts to blur that line.

Its Lab-in-the-Loop platform runs experiments, feeds results directly into machine learning models, and uses those models to guide the next round of testing. That creates a continuous cycle where data and intelligence refine each other rather than sitting in separate silos.

What makes this relevant to industry isn’t just curiosity about microbes. Microbiological interactions shape how drugs are metabolised, how nutrients are processed and how formulations behave in the body. At present, many pharmaceutical, food and consumer products companies have to work with incomplete or indirect evidence about those effects.